What's Happening?
CREATE Medicines, a biotechnology company based in Cambridge, Massachusetts, has successfully raised $122 million in a Series B funding round. The funding, co-led by Newpath Partners, ARCH Venture Partners, and
Hatteras Venture Partners, will be used to advance the company's clinical pipeline, which focuses on in vivo CAR T therapies for autoimmune diseases and cancer. CREATE's proprietary mRNA-LNP platform allows for the direct engineering of immune cells within the body, aiming to streamline the transition from concept to clinical application. The company has already dosed over 50 patients, establishing a significant clinical dataset in the field. The funds will support the development of therapies such as CRT-402, a CD19-targeted in vivo CAR-T therapy, and a dual CAR CD19 x BCMA therapy, both of which are designed to address refractory autoimmune conditions.
Why It's Important?
The significant investment in CREATE Medicines underscores the growing interest and potential in in vivo CAR T therapies, which offer a novel approach to treating autoimmune diseases and cancer. By engineering immune cells directly within the body, CREATE aims to provide scalable, repeat-dose therapies that could transform current treatment paradigms. This approach could lead to more efficient and accessible treatments, reducing the time and cost associated with traditional CAR T therapies. The success of CREATE's platform could have wide-reaching implications for the biotechnology industry, potentially setting new standards for the development and delivery of immunotherapies.
What's Next?
With the new funding, CREATE Medicines plans to push its lead programs further into clinical trials, particularly focusing on therapies for autoimmune diseases and oncology. The company will continue to build on its existing clinical data, aiming to demonstrate the efficacy and safety of its in vivo CAR T therapies. The addition of Ron Philip as Executive Chairman and new board members from ARCH Venture Partners and Newpath Partners suggests a strategic focus on expanding the company's reach and capabilities. As CREATE advances its pipeline, it will likely seek further partnerships and collaborations to enhance its clinical and commercial prospects.
